UBS Upgrades Corcept Therapeutics to Buy, Raises Price Target to $72
Benzinga Newsdesk 6 months ago
NewsUpgradesPrice TargetAnalyst Ratings
UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and raises the price target from $44 to $72.
UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and raises the price target from $44 to $72.